The Kano trovafloxacin trial litigation arose out of a clinical trial conducted by the .... ever been treated with Trovan, and then only after all other antibiotics failed.


Summary of this case from Kiobel v. .... Pfizer International, Inc., [2001] Suit No. ..... M. Cheriff Bassiouni et al., An Appraisal of Human Experimentation in ...


Jan 19, 2018 ... In Wyeth v. Levine, the Supreme Court held that claims against a manufacturer of a brand-name prescription drug for failure to warn adequately ...


Jul 27, 2017 ... Palbociclib (IBRANCE®; Pfizer Inc, New York, NY, USA) is a new oral cyclin- dependent kinase ... All references used in two previous NMAs by Generali et al. .... Model fit statistics, Residual deviance = 25.08 vs. ..... Migliaccio I, Malorni L, Hart CD, Guarducci C, Di Leo A. Endocrine therapy considerations in ...


Jul 29, 2010 ... For all markers, the pan-cytokeratin signal was used to create an epithelial “mask ” to distinguish .... to those tumors with squamous cell histology (Figure 3B (SQ), median AQUA scores 5,885 vs. ..... Disclosures: This research was supported by Pfizer Inc. ... Gustavson MD, Bourke-Martin B, Reilly DM, et al.


7/13/2016 · 3:16-cv-03922 · Schaaf-Richards v. Volkswagen Group of America, Inc. et al ...... 3:07-cv-06497-CRB · Abad v. Bronson & Migliaccio. LLP et al ...


Of these, 5.8% switched, 51.3% permanently discontinued all anticholinergic agents, and .... Detrol, Detrol LA and Toviaz (Pfizer Inc., New York, New York). ‡ .... switches are almost one third the rate observed by D'Souza et al (5.8% vs 13 %). ... Ms. Migliaccio-Walle led the manuscript preparation, provided oversight and ...


Mar 10, 2016 ... postmenopausal patients with all stages of ER ю breast cancer (1). ...... Luca Malorni, Mario Giuliano, Ilenia Migliaccio, et al. Resistance.


Mar 5, 2015 ... Ilenia Migliaccio,; Luca Malorni,; Christopher D Hart,; Cristina Guarducci and; Angelo Di LeoEmail ... Migliaccio et al.; licensee BioMed Central.